April 17, 2017 / 8:31 PM / 2 years ago

BRIEF-Aurinia completes licensing deal with Merck Animal Health

April 17 (Reuters) - Aurinia Pharmaceuticals Inc-

* Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome

* Aurinia Pharma-signed agreement granting merck animal health worldwide rights to develop, commercialize co’s nanomicellar voclosporin ophthalmic solution

* Aurinia Pharma-under deal, co will receive upfront payment, is eligible to receive further payments based on certain development and sales milestones

* Aurinia Pharmaceuticals Inc- under deal, aurinia will receive royalties based on global product sales

* Aurinia Pharma- under deal merck animal health to be responsible for remaining clinical development, commercialization of vos for use in animal health field

* Aurinia pharmaceuticals inc- under deal aurinia retains all human health rights related to vos Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below